RecentlyMedtronic Senior Vice President and President of Peripheral Vascular Health Business Dave Moeller Introduces Medtronic 2025Planning and Market Response Strategy: Medtronic willFocus on carotid artery treatment, thrombectomy, and BTK diseases, while phasing out AVF anastomosis.Dave Moeller stated: In the next 1-2 years, the number of new product launches in Medtronic's peripheral sector will surpass the total of the past five years. Medtronic is entering a period of innovation explosion, focusing on its areas of strength to address the most pressing unmet needs in peripheral vascular care.The following is Medtronic's layout in the peripheral field.
Last year, Medtronic entered into a strategic partnership with Contego Medical, and Medtronic obtainedContego Medical's Stent + Balloon Dilation + Embolic Protection Triple-Function Carotid Artery Stent Neuroguard ExclusiveDistribution rights, and forCorrectContego MedicalMake investments while gaining acquisitionsContego MedicalOption.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Medtronic has already done so in May this year.TakeoverNeuroguardDistribution rights. MeanwhileContego Medical is also actively promotingTranscarotid ApproachClinical Research of Neuroguard IEP Direct (PERFORMANCE III），Expected to complete enrollment this year.
Due toThe expansion of Medicare's reimbursement scope for CAS in 2023, coupled withNeuroguardClinical trial success.Carotid artery business becomes the strategic core of Medtronic's peripheral business again.
Dave Moeller said: It will be implemented in phases.NeuroguardCommercialization: First cover high-volume surgery centers, then expand to medium and low-scale centers, providing initial training and ongoing support. Medtronic's extensive sales channels for peripheral vascular and neurovascular productsNeuroguardOffers unique advantages for promotion.PAD is currently the largest market in the peripheral field and also a key peripheral sub-sector that Medtronic focuses on. However, there have been recent clinical doubts.Data and Overuse of Peripheral Artery Plaque Excision. Dave Moeller responded: A systematic literature review conducted by Medtronic in collaboration with top vascular experts revealed over 300 existing studies on plaque excision (including 11 meta-analyses, 18 randomized controlled trials, and numerous observational studies). The research shows that plaque excisionSafe and effective for all subgroups of patients with above-the-knee/below-the-knee lesions, calcification, claudication, and chronic limb-threatening ischemia. AlreadyDetailed study data were presented at the CX 2025 conference.In the PAD field, what Medtronic focuses on most isDrug-Coated Balloon (DCB). Medtronic is currently expanding its peripheral DCB project portfolio, planning to add longer balloon sizes compatible with 0.018-inch guidewires and indications for below-the-knee use."In the DCB field, we have long maintained a global leadership position and are now committed to extending our advantages to below-the-knee lesions. New technology iterations and clinical trial preparations are currently underway."- Venous Diseases and Peripheral Thrombectomy
The venous field is about to launch a new mechanical thrombectomy system, Liberant. LiberantIntegrating the technological advantages of the Neurovascular Division, and combining innovations in blood protection and catheter technology. Medtronic can leverage the existing experience of the Abre venous stent to accelerate its strategic layout. Additionally,Contego MedicalThe developed Excipio (a combination device of a variable-diameter thrombectomy stent and an aspiration catheter) can be used in conjunction with Medtronic's existing mechanical aspiration system.In the field of superficial venous treatment, Medtronic has invested in the VenaSeal Spectrum project (comprising two randomized trials and one single-arm study). The latterCX 2025 ConferencePublication: Focusing on Wound Healing in CEAP Stage 6 Patients After VenaSeal Treatment. Addressing Resistance in the Superficial Vein Market,Dave MoellerStraight Talk: "The Core Challenge Lies in Medical Insurance Reimbursement." Stabilizing rates and securing reimbursement from remaining payers who do not yet cover VenaSeal have become the top priorities.
In the dialysis access field, In.Pact AV DCB will remain the global growth driver. Meanwhile, Medtronic has decided to exit the arteriovenous fistula anastomosis market (the Ellipsys platform, which has been continuously invested in for four years, will cease support).
PauseReasons for Ellipsys:
WantIt is difficult to change the gold standard for AVF pathway establishment. DespiteThe Ellipsys interventional anastomosis technique is excellent, butThe AVF created by Ellipsys is a low-flow arteriovenous fistula, unlike those created through surgical procedures.Arteriovenous FistulaThat high blood flow, and the difficulty of AVF puncture created by Ellipsys is also greater than that of surgical creation.Arteriovenous fistula. Although some doctorsEllipsys is highly regarded, but most doctors do not approve. In the end, Medtronic believes that the current market scale cannot support it.Ellipsys was profitable, so the project had to be stopped.
